- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Erasca Inc(ERAS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ERAS
11/13/2026: ERAS (1-star) is currently NOT-A-BUY. Pass it for now.
Erasca Inc is a clinical-stage precision oncology company focused on discovering and developing targeted therapies to shut down the RAS/MAPK signaling pathway in cancer patients. The company's primary strengths lie in its specialized scientific expertise, a robust pipeline featuring assets like ERAS-0015 and ERAS-4001, and a strong cash position that provides a healthy operational runway. Its main investment story centers on the potential to unlock high-value treatments for mutation-driven solid tumors and attract potential partnership or acquisition interest. However, the company faces significant clinical, regulatory, and execution risks typical of pre-revenue biotechnology firms. Erasca represents a speculative fit suited primarily for growth-oriented investors willing to monitor clinical data readouts and regulatory updates closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | High potential upside tied to clinical pipeline expansion in major oncology markets appeals to aggressive growth strategies. |
| Momentum investor | Strong fit while signal remains positive | Stock reacts sharply to clinical trial readouts, data presentations, and sector-wide M&A speculation, creating strong short-term momentum windows. |
| Value investor | Weak fit | The lack of commercial revenues, ongoing operational cash burn, and clinical-stage status make traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company pays no dividends and reinvests all capital into clinical research and drug development. |
| Low-risk investor | Weak fit | High clinical, regulatory, and price volatility risks make the stock unsuitable for conservative risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Stock prices fluctuate dramatically based on clinical trial updates, regulatory decisions, and biotech market sentiment. |
| Valuation risk | High | Valuations are driven by clinical pipeline expectations rather than current earnings or cash flows. |
| Competition risk (targeted oncology and RAS pathway inhibition) | High | Numerous well-capitalized biotech and pharmaceutical peers are developing competing RAS-targeted oncology drugs. |
| Business quality | Medium | The company possesses strong scientific expertise and solid cash reserves, but lacks commercial operational maturity. |
| Dividend income | Low / none | No dividend is paid or anticipated as capital is prioritized entirely for drug development. |
| Execution risk | High | Success depends entirely on successfully executing clinical trials, overcoming regulatory hurdles, and achieving positive efficacy data. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.50B USD | Price to earnings Ratio - | 1Y Target Price 24.11 |
Price to earnings Ratio - | 1Y Target Price 24.11 | ||
Volume (30-day avg) 5.5M shares | Beta 0.65 | 52 Weeks Range 2.52 - 24.28 | Updated Date 11/15/2026 |
52 Weeks Range 2.52 - 24.28 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.97 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -2.2% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Commercial sales of approved therapeutic drugs. | Erasca currently generates no commercial product revenue as its drug pipeline remains in clinical development. |
| Collaborations and Grants | Upfront licensing fees, milestone payments, and research grants from strategic partnerships. | Any near-term financial inflows outside of capital raises typically stem from research partnerships or licensing agreements with pharmaceutical collaborators. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4.89B | Price to Sales(TTM) - |
Enterprise Value 4.89B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.57 | Shares Outstanding 350.96M | Shares Floating 256.41M |
Shares Outstanding 350.96M | Shares Floating 256.41M | ||
Percent Insiders 6.71 | Percent Institutions 95.67 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

